HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis.

AbstractBACKGROUND:
Quantitative analysis of intravenous immunoglobulin (IVIg) treatment against toxic epidermal necrolysis (TEN) is lacking.
OBJECTIVES:
To provide a meta-analysis evidence-based examination of IVIg efficacy against TEN.
METHODS:
A systematic review and meta-analysis of literature published before 31 July 2011 was conducted. In observational controlled studies with at least eight patients with TEN receiving IVIg treatment, a pooled estimate of mortality risk was determined, comparing IVIg and supportive care. Statistical analyses were performed on raw data to compare the clinical differences between (i) high-dose and low-dose IVIg treatment in adult patients and (ii) paediatric and adult patients treated with IVIg.
RESULTS:
Seventeen studies met inclusion criteria. Overall mortality rate of patients with TEN treated with IVIg was 19.9%. The pooled odds ratio (OR) for mortality from six observational controlled studies comparing IVIg and supportive care was 1.00 [95% confidence interval (CI) 0.58-1.75; P=0.99]. The pooled OR for mortality in patients treated with high-dose IVIg vs. supportive care was 0.63 (95% CI 0.27-1.44; P=0.27). Adults treated with high-dose IVIg exhibited significantly lower mortality than those treated with low-dose IVIg (18.9% vs. 50%, respectively; P=0.022); however, multivariate logistic regression model adjustment indicated that IVIg dose does not correlate with mortality (high vs. low dose: OR 0.494; 95% CI 0.106-2.300; P=0.369). Paediatric patients treated with IVIg had significantly lower mortality than adults (0% vs. 21.6%; P=0.001).
CONCLUSIONS:
Although high-dose IVIg exhibited a trend towards improved mortality and children treated with IVIg had a good prognosis, the evidence does not support a clinical benefit of IVIg. Randomized controlled trials are necessary.
AuthorsY-C Huang, Y-C Li, T-J Chen
JournalThe British journal of dermatology (Br J Dermatol) Vol. 167 Issue 2 Pg. 424-32 (Aug 2012) ISSN: 1365-2133 [Electronic] England
PMID22458671 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Copyright© 2012 The Authors. BJD © 2012 British Association of Dermatologists.
Chemical References
  • Immunoglobulins, Intravenous
Topics
  • Adolescent
  • Adult
  • Aged
  • Child
  • Epidemiologic Methods
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Length of Stay
  • Middle Aged
  • Stevens-Johnson Syndrome (drug therapy)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: